NCT02872285View on ClinicalTrials.gov

An Efficacy and Safety Study of LYC-30937-EC in Subjects With Moderate Chronic Plaque-type Psoriasis

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

December 5, 2016

Primary Completion Date

June 22, 2017

Study Completion Date

June 22, 2017

Conditions
Psoriasis
Interventions
DRUG

Drug: LYC-30937-EC

DRUG

Placebo

Trial Locations (7)

19008

Lycera Investigational Site, Broomall

23502

Lycera Investigational Site, Norfolk

27262

Lycera Investigational Site, High Point

46032

Lycera Investigational Site, Carmel

55432

Lycera Investigational Site, Fridley

01810

Lycera Investigational Site, Andover

08520

Lycera Investigational Site, East Windsor

All Listed Sponsors
lead

Lycera Corp.

INDUSTRY

NCT02872285 - An Efficacy and Safety Study of LYC-30937-EC in Subjects With Moderate Chronic Plaque-type Psoriasis | Biotech Hunter | Biotech Hunter